Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,728.80
(
-0.28%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.67
(
3.84%
)
Bitcoin
70,068.95
(
-1.65%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 89977

Friday, 08/20/2010 6:10:58 AM

Friday, August 20, 2010 6:10:58 AM

Post# of 257257
Sigmapharm Laboratories files Paragraph-IV challenge for GILD’s Hepsera:

http://finance.yahoo.com/news/Gilead-Sciences-Announces-bw-974569144.html?x=0&.v=1

The obvious question is: Why bother? For all practical purposes, Hepsera has been superseded by Viread. Even if Sigmapharm prevails in the patent litigation, by the time the 30-month Hatch-Waxman stay expires, US Hepsera sales will not amount to much.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now